Exelixis has patented a method for treating castration-resistant prostate cancer and osteoblastic bone metastases using a dual inhibitor of MET and VEGF. The patent claims administering Compound 1 to patients in need of treatment. GlobalData’s report on Exelixis gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Exelixis, Cancer treatment biomarkers was a key innovation area identified from patents. Exelixis's grant share as of May 2024 was 30%. Grant share is based on the ratio of number of grants to total number of patents.
Dual inhibitor for treating castration-resistant prostate cancer and bone metastases
A recently granted patent (Publication Number: US11969419B2) discloses a method for treating castration-resistant prostate cancer (CRPC) or osteoblastic bone metastases associated with CRPC. The method involves administering a therapeutically effective amount of Compound 1 to a patient in need of such treatment. Compound 1 can be in the form of the malate salt, specifically the (L)- or (D)-malate salt, and can be administered as a pharmaceutical composition along with a pharmaceutically acceptable carrier, excipient, or diluent.
This method not only targets CRPC but also focuses on treating osteoblastic bone metastases associated with CRPC. By utilizing Compound 1 in the specified forms and compositions, the patent aims to provide an effective treatment option for patients suffering from these conditions. The inclusion of pharmaceutically acceptable salts and carriers in the administration of Compound 1 enhances the delivery and efficacy of the treatment, potentially improving patient outcomes in the management of CRPC and associated bone metastases.
To know more about GlobalData’s detailed insights on Exelixis, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
